Founded in 2000, Kasai biology is a high-tech enterprise based on synthetic biology and other disciplines, using biological manufacturing technology to engage in the research and development, production and sales of new bio based materials.
Since its establishment, after nearly 20 years of R & D investment and technology accumulation, the company has accumulated profound experience in the field of biological manufacturing, and has developed into a world-famous platform for R & D and manufacturing of biological manufacturing theory and technology and industrial methods, and has more than 100 patents.
As a revolutionary mode of production, biological manufacturing uses biomass as raw material or biological methods for large-scale material processing and transformation, and provides industrial commodities (such as new materials and products) for social development. The production process is green, mild and economical, which can solve the excessive dependence of human beings on traditional petrochemical and chemical products, As well as the accompanying environmental pollution, safety risks and other effective ways, the future development space is very broad.
It is reported that in Chinas 13th five year plan for national science and technology innovation and the 13th five year plan for biotechnology innovation, synthetic biotechnology has been listed as one of the subversive technologies to develop and lead industrial changes required for building a modern industrial technology system with international competitiveness.
Kaisai bio is currently a representative and market influential leading enterprise in the large-scale production of long-chain dicarboxylic acid series products by biotechnology. The products occupy a leading position in the global market, and were rated as the single champion of the manufacturing industry by the Ministry of industry and information technology in 2018.
Biological long chain dicarboxylic acid series products usually refer to aliphatic dicarboxylic acids with ten or more carbon atoms in the carbon chain, which are important fine chemical intermediates. Traditionally, it is mainly produced by chemical method, while Kasai biological process adopts biological method, which has the advantages of richer product types, lower cost and more environmental protection. It is mainly used for high-performance long-chain polyamide, perfume, hot-melt adhesive, lubricating oil, cold resistant plasticizer, powder coating, etc.
Kaisai biological long-chain dicarboxylic acid products have been recognized by international well-known enterprises, including DuPont, emmans, Evonik, Novo Nordisk and other global famous chemical and pharmaceutical enterprises.
According to the financial data, from 2017 to 2019, Casa bio achieved revenue of 1.363 billion yuan, 1.757 billion yuan and 1.916 billion yuan, and realized net profits of 333 million yuan, 466 million yuan and 479 million yuan respectively.
The main business income of the company mainly comes from the sales revenue of biological manufacturing products. Among them, the proportion of biological long-chain dicarboxylic acid income in the main business income is 99.62%, 99.70% and 99.56% respectively.
In addition to biological long-chain dicarboxylic acid products, biogenic pentanediamine and bio Based Polyamide are also the main products of Kasai bio. Such achievements in the field of biological manufacturing are closely related to the R & D level of Kasai.
Business model with R & D as the core
Casa bio has R & D teams in the fields of synthetic biology, cell engineering, biochemistry, polymer materials and engineering. The company adopts the R & D mode of independent R & D and cooperative R & D.
The company has accumulated a large number of research and development achievements in the fields of synthetic biology, cell engineering, biochemistry, polymer materials and engineering, and its core technologies are applied to the companys main business. Up to now, Kasai has formed four core technologies in genetic engineering, bioengineering, bio chemical industry, polymerization and application development of biopolymer materials, which are protected by combining patent and trade secret.
In terms of bioengineering, Kasai biologicals microbial metabolism regulation and efficient microbial transformation technology uses online sensor technology to collect various physiological parameters of biological metabolism process, conduct big data analysis, and implement intelligent control process.
In the aspect of biochemical industry, the separation and purification technology of the companys biotransformation / fermentation system effectively realizes the impurity removal process of biological manufacturing.
In the process of in-depth research and development of the above four core technologies to enhance the competitiveness of products and reduce the cost of products, the quality and performance of Kasai biological products are also constantly improved. Up to now, the purity, transmittance and thermal stability of biological long-chain dicarboxylic acid (DC12 as an example) of the company, the companys indicators for biological polymerization products, and the color stability under high temperature detection are far better than those of similar products on the market.
Pentanediamine, bio Based Polyamide (pa56 industrial grade as an example) of various indicators is to achieve the market exclusive favorite state. It is reported that there are no other industrial products on the market to compare with these two products.
It can be seen that the achievements of Kasai biology in the field of biological manufacturing are beyond the reach of ordinary enterprises. In addition, the technical barriers created by the companys huge patent pool are enough to leave many similar enterprises behind, which also proves that Kasai attaches great importance to R & D investment.
During the reporting period, the R & D investment amount of Kasai biological increased year by year, and the proportion was stable. From 2017 to 2019, the companys R & D expenses were 64.5602 million yuan, 86.3938 million yuan and 90.1595 million yuan, accounting for 4.74%, 4.92% and 4.71% of the current operating income respectively.
R & D system to upgrade biological manufacturing enterprises
This time, the company plans to raise 4.699 billion yuan, which will be used for the construction and investment of the 40000 t / a biological sebacic acid project of Kaisai (Jinxiang) biomaterials Co., Ltd., the bio Based Polyamide Engineering Technology Research Center, the annual production of 30000 tons of long-chain dicarboxylic acid and 20000 tons of long-chain polyamide project of Kaisai (Wusu) Biotechnology Co., Ltd., as well as supplementary working capital.
It is reported that Kasai bio Based Polyamide Engineering Technology Research Center aims to enhance the R & D strength of the company in the field of polyamide products, which is conducive to further upgrading and improving the companys technology R & D system, and establishing a systematic research and Development Center for bio based polyamide products, which is of great significance to support the implementation of casais R & D and innovation strategy.
Kaisai Bio said that the company adheres to the R & D driven strategy, continues to develop R & D in the theoretical research and industrial practice of bio manufacturing, pays attention to the combination of R & D and market, and R & D and production, and leads the direction of technology R & D with effective market demand. The companys main business model is to continuously transfer technical advantages to productivity through continuous research and development, improving production process, reducing costs and improving quality.
For example, in the aspect of pentanediamine, Kaisai bio based pentanediamine technology has made continuous breakthroughs. So far, it has completed the pilot test, which is expected to solve the main bottleneck of the development of the bimonor polyamide industry. The companys production of glutamine is mainly used for the production of its own polyamide series products, and some of them are provided to downstream customers for application and development. The companys bio based pentanediamine products have been verified by downstream international customers and have been used in automobile surface coatings. This application has won the ecsinnovation award.
Another example is bio based polyamide. Based on the polycondensation of biogenic glutamine and different dibasic acids, Casa bio based polyamide products, such as polyamide 56, have the characteristics of high strength, wear resistance, flame retardancy, moisture absorption and good resilience, which can be widely used in the fields of textile and clothing, carpet, industrial silk, etc.
At present, the company has cooperated with spinning, cloth and carpet enterprises to develop a series of products such as civil silk, carpet silk and industrial silk of polyamide 56; the company has successfully developed polyester amide fiber products with super cotton like properties by modifying polyester fiber with bio based materials.
It is reported that the self owned textile material Talon made by Kasai biology has been selected as the most concerned fiber product in the 2017 China International Textile yarn (spring and summer) exhibition, and has been selected as China fiber fashion trend for two consecutive years.
At present, the company is planning to build high-performance long-chain polyamide production capacity. In the future, the company will further develop the long-chain polyamide market relying on its own advantages of long-chain dicarboxylic acid and pentanediamine.
It is reported that Kasai biological products cover the whole industrial chain of polyamide, including Bio Based Polyamide and its monomer, biological long-chain dicarboxylic acid series and biogenic pentanediamine. Around the industrial chain, the company has planned a three-step development strategy, that is, the strategy of biological long-chain dicarboxylic acid series products, the product strategy of bio based pentanediamine and the product strategy of bio based polyamide. The three-step development strategy shows that Kasai bio has certified its own strength, and this confidence comes from its hard core innovation and research ability. From the core technology of biological long-chain dicarboxylic acid series products to bio based polyamide, and then to biogenic pentanediamine, Casa bio has always used its own strength to tell the story of Chinese enterprises on the world stage, show the strength of Chinese enterprises, and gradually grow into a benchmark enterprise in the field of biological science. Source: editor in charge of mass news: Chen Tiqiang_ NB6485
It is reported that Kasai biological products cover the whole industrial chain of polyamide, including Bio Based Polyamide and its monomer, biological long-chain dicarboxylic acid series and biogenic pentanediamine. Around the industrial chain, the company has planned a three-step development strategy, that is, the strategy of biological long-chain dicarboxylic acid series products, the product strategy of bio based pentanediamine and the product strategy of bio based polyamide.
The three-step development strategy shows that Kasai bio has certified its own strength, and this confidence comes from its hard core innovation and research ability. From the core technology of biological long-chain dicarboxylic acid series products to bio based polyamide, and then to biogenic pentanediamine, Casa bio has always used its own strength to tell the story of Chinese enterprises on the world stage, show the strength of Chinese enterprises, and gradually grow into a benchmark enterprise in the field of biological science.